Randomized Phase II Trial of VK2809, an Investigational Thyroid Hormone Receptor Agonist, vs Placebo in NAFLD With Hyperlipidemia

April 10-14, 2019; Vienna, Austria
Patients treated with VK2809 for 12 weeks showed significantly reduced LDL-C and liver fat content vs those treated with placebo.
Format: Microsoft PowerPoint (.ppt)
File Size: 179 KB
Released: April 22, 2019

Acknowledgements

Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Educational grant provided by:
AbbVie
Gilead Sciences

Related Content

Hear CCO faculty Philip Newsome discuss the agents in late-phase clinical trials and their potential use in treatment of NASH and fibrosis

Philip N. Newsome, PhD, FRCPE Released: February 12, 2020

CCO faculty Dr Juan Frias discusses the agents in late-phase clinical trials and their potential use in treatment of NASH and fibrosis

Juan Pablo Frias, MD, FACE Released: February 5, 2020

Juan Frias and Philip Newsome: Learn about the agents in phase II and III clinical trials and their potential use in treatment.

Juan Pablo Frias, MD, FACE Philip N. Newsome, PhD, FRCPE Released: January 28, 2020

Hear CCO faculty Rita Basu, MD, weigh the latest perspectives on wet biomarkers, imaging, and combination tests

Rita Basu, MD Released: January 23, 2020

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.

Continue

More info

CCO’s educational programs are available completely free of charge on the ClinicalOptions.com, inPractice.com, and inPracticeAfrica.com Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?